Highlights
- •PD patients have higher SNpc brain iron than controls.
- •PD patients have higher SNpc/White Matter brain iron ratio than controls.
- •PD patients have higher SNpc/serum iron ratio than controls.
Abstract
Brain iron has been previously found elevated in the substantia nigra pars compacta
(SNpc), but not in other brain regions, of Parkinson's disease (PD) patients. However,
iron in circulation has been recently observed to be lower than normal in PD patients.
The regional selectivity of iron deposition in brain as well as the relationship between
SNpc brain iron and serum iron within PD patients has not been completely elucidated.
In this pilot study we measured brain iron in six regions of interest (ROIs) as well
as serum iron and serum ferritin, in 24 PD patients and 27 age- gender-matched controls.
Brain iron was measured on magnetic resonance imaging (MRI) with a T2 prime (T2′)
method. Difference in brain iron deposition between PD cases and controls for the
six ROIs were calculated. SNpc/white matter brain iron ratios and SNpc/serum iron
ratios were calculated for each study participant, and differences between PD patients
and controls were tested. PD patients overall had higher brain iron than controls
in the SNpc. PD patients had significantly higher SNpc/white matter brain iron ratios
than controls, and significantly higher brain SNpc iron/serum iron ratios than controls.
These results indicate that PD patients' iron metabolism is disrupted toward a higher
partitioning of iron to the brain SNpc at the expenses of iron in the circulation.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Parkinson's disease.Lancet. 2009; 373: 2055-2066
- Increased nigral iron content in postmorterm Parkinsonian brain.Lancet. 1987; 2: 1219-1220
- Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy.Brain. 1999; 122: 667-673
- Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.Brain. 2000; 123: 2423-2431
- MRI assessment of basal ganglia iron deposition in Parkinson's disease.J. Magn. Reson. Imaging. 2008; 28: 1061-1067https://doi.org/10.1002/jmri.21563
- Clinical MRI for iron detection in Parkinson's disease.Clin. Imaging. 2013; 7: 631-636
- Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.Neurology. 2008; 70: 1411-1417
- The relevance of iron in the pathogenesis of Parkinson's disease.Ann. N. Y. Acad. Sci. 2004; 1012: 193-208
- Altered brain metabolism of iron as a cause of neurodegenerative disease?.J. Neurochem. 1994; 63: 793-807
- Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.Drugs Aging. 2001; 18: 685-716
- Intranigral iron injection induces behavioural and biochemical “parkinsonism” in rats.J. Neurochem. 1991; 57: 2133-2135
- Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.Ann. N. Y. Acad. Sci. 2004; 1012: 306-325
- Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Antioxid. Redox Signal. 2014; 21: 195-210
- Iron in parkinsonian and control substantia nigra – Mössbauer spectroscopy study.Mov. Disord. 1996; 11: 8-16
- Human nigral an liver iron-comparison by Mössbauer spectroscopy, electron microscopy, and ELISA.Hyperfine Interact. 2005; 165: 285-288
- A quantitative analysis of isoferritins in select regions of aged, parkinsonian and Alzheimer's diseased brains.J. Neurochem. 1995; 65: 717-724
- The role of the L-chain in ferritin iron incorporation.J. Mol. Biol. 1994; 238: 649-654
- ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control.Parkinsonism Relat. Disord. 2007; 13: 214-218
- Imaging iron stores in the brain using magnetic resonance imaging.Magn. Reson. Imaging. 2005; 23: 1-25
- Modifications of the iron-neuromelanin system in Parkinson's disease.J. Neurochem. 2006; 96: 909-916
- Iron and reactive oxygen species activity in parkinsonian substantia nigra.Parkinsonism Relat. Disord. 2010; 16: 329-333
- Potential sources of increased iron in the substantia nigra of parkinsonian patients.J. Neural Transm. Suppl. 2006; 70: 133-142
- High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease.J. Magn. Reson. Imaging. 2012; 35: 48-55
- Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms.Front. Pharmacol. 2014; 5: 99https://doi.org/10.3389/fphar.2014.00099
- G Becker, O. Riess, D. Berg. Functional relevance of ceruloplasmin mutations in Parkinson's disease.FASEB J. 2005; 19: 1851-1853
- Ceruloplasmin gene variation and substantia nigra hyperechogenicity in Parkinson disease.Neurology. 2004; 63: 1912-1917
- Ceruloplasmin dysfunction and the therapeutic potential for Parkinson disease.Ann. Neurol. 2013; 73: 554-559https://doi.org/10.1002/ana.23817
- Is R2* a new MRI biomarker for the progression of Parkinson' s disease? A longitudinal follow-up.PLoS One. 2013; 8e57904
- Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson disease.Neurology. 2013; 80: 492-495
- Altered systemic iron metabolism in Parkinson's disease.Neurology. 1997; 49: 714-717
- Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk.Parkinsonism Relat. Disord. 2015; 21: 1087-1092
- Blood donations, iron stores, and risk of Parkinson's disease.Mov. Disord. 2006; 21: 835-838
- Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study.Neurology. 2009; 73: 1381-1387
- Serum iron levels and risk of Parkinson's disease: a Mendelian randomization study.PLoS Med. 2013; 10e1001462
- Peripheral iron metabolism in patients with Parkinson's disease.J. Neurol. Sci. 1994; 125: 82-86
- Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease.J. Neural Transm. 1998; 105: 497-505
- A comparison of clinical pathological features of young- and old-onset Parkinson's disease.Neurology. 1988; 38: 1402-1406
- Human circadian rhythms in termperature, trace metals, and blood variables.J. Appl. Physiol. 2005; 65: 1840-1846
- MRI measurement of brain iron in patients with restless legs syndrome.Neurology. 2001; 56: 263-265
- Brain iron deposition and sequence characteristics in parkinsonism comparison of SWI, T2* maps, T2-weighted-, and FLAIR-SPACE.Investig. Radiol. 2010; 45: 795-802
- Pooled analysis of tobacco use and risk of Parkinson disease.Arch. Neurol. 2007; 64: 990-997
- Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys.Free Radic. Biol. Med. 2003; 35: 540-547
- Iron homeostasis in health and disease.Int. J. Mol. Sci. 2016; 17: E130https://doi.org/10.3390/ijms17010130
- Neuroferritionopathy: a neurodegenerative disorder associated with L-ferritin mutation.Best Pract. Res. Clin. Haematol. 2005; 18: 265-276
- Iron and ferritin levels of patients with thalassemia and iron deficiency anemia.Mediterr. J. Hematol. Infect. Dis. 2012; 4: e2012051https://doi.org/10.4084/MJHID.2012.051
- Calcium, copper, iron, magnesium, silicon and zinc content of hair in Parkinson's disease.J. Trace Elem. Med. Biol. 2005; 19: 195-201
- The association between the C282Y and H63D polymorphism of HFE gene and the risk of Parkinson's disease: a meta-analysis.Neurosci. Lett. 2015; 595: 99-103https://doi.org/10.1016/j.neulet.2015.04.010
Article info
Publication history
Published online: April 22, 2017
Accepted:
April 21,
2017
Received in revised form:
March 27,
2017
Received:
October 28,
2016
Identification
Copyright
© 2017 Elsevier B.V. All rights reserved.
